Acute pancreatitis is an inflammatory condition that may lead to multi-systemic organ failure with considerable mortality. Recently, resolvin D1 (RvD1) as an endogenous anti-inflammatory lipid mediator has been confirmed to protect against many inflammatory diseases. This study was designed to investigate the effects of RvD1in acute pancreatitis and associated lung injury. Acute pancreatitis varied from mild to severe was induced by cerulein or cerulein combined with LPS, respectively. Mice were pretreated with RvD1 at a dose of 300ng/mouse 30 min before the first injection of cerulein. Severity of AP was assessed by biochemical markers and histology. Serum cytokines and myeloperoxidase (MPO) levels in pancreas and lung were determined for assessing the extent of inflammatory response. NF-κB activation was determined by western blotting. The injection of cerulein or ceulein combined with LPS resulted in local injury in the pancreas and corresponding systemic inflammatory changes with pronounced severity in the ceulein and LPS group. Pretreated RvD1 significantly reduced the degree of amylase, lipase, TNF-α and IL-6 serum levels, the MPO activities in the pancreas and the lungs, the pancreatic NF-κB activation, the severity of pancreatic injury and associated lung injury, especially in the severe acute pancreatitis model. These results suggest that RvD1 is capable of improving injury of pancreas and lung, and exerting anti-inflammatory effects may through the inhibition of NF-κB activation in experimental acute pancreatitis, with more notable protective effect in severe acute pancreatitis.
Introduction
Acute pancreatitis is an inflammatory disorder of the exocrine pancreas. Although most patients suffer a mild and limited disease, about one-fifth of cases develop acute respiratory distress syndrome and multiple organ dysfunction, accompanied by high mortality (8) . Specific and effective interventions for this disease are not available largely because of a lack of understanding of the early cellular events in its pathophysiology. Nuclear factor-κB (NF-κB) is a ubiquitous inducible transcription factor and composed of a group of structurally related transcriptional proteins (15) . In pancreas, the predominant form of NF-κB is p65/p50 heterodimer (12, 28) . Under control conditions, NF-κB is kept inactive in the cytoplasm through sequestration in complexes with the inhibitor of κB (IκB) proteins, such as IκB-α and IκB-β. The sequestration prevents NF-κB migration into the nucleus, its' binding to DNA, and transcriptional activation. Typically, in response to an inducing stimulus the IκBs are phosphorylated on specific Ser residues by IκB kinases (IKKs), which results in IκB ubiquitylation and proteasome-mediated degradation, allowing NF-κB nuclear translocation (11, 28) . NF-κB is activated early in acinar cells during acute pancreatitis and increases expression of multiple pro-inflammatory genes, such as TNF-α and IL-6 (9, 36) . In most studies, pharmacologic inhibition of NF-κB resulted in an amelioration of inflammatory response, necrosis, and other parameters of pancreatitis severity (7, 29, 31) .
Moreover, a recent study showed that increased acinar cell NF-κB activity correlated with higher cytokine expression and greater severity of acute pancreatitis using novel genetic mouse models (13) . Thus, specific and effective drugs which inhibiting NF-κB activation can be useful in therapy of acute pancreatitis. However, no innovative drugs are so far available in the clinical setting (23) .
Omega-3 polyunsaturated fatty acids (n-3PUFAs), namely eicosapentaenoic acid (EPA) and 4 docosahexaenoic acid (DHA), which are enriched in some fish oils, are believed to exert beneficial effects on a wide range of inflammatory disorders (30, 40) , including acute pancreatitis (1, 24) . EPA and DHA originate the lipid mediators known as resolvins, which regulate critical cellular events in the resolution of inflammation (32, 33) . Resolvin D1 (7S, 8R, 17S-trihydroxy DHA, RvD1) is one of the resolvins and is derived from DHA (34). RvD1 can inhibit neutrophil activation (16, 38) , regulate cytokines (18, 39) and inhibit the activation of NF-κB pathway in endotoxin (lipopolysaccharide, LPS) induced inflammatory response (4, 6, 18, 21, 42) . It has also been identified to reverses chronic pancreatitis-induced chronic pain (27) .
Overall, these observations prompted us to hypothesize that RvD1 maybe have protective effects on acute pancreatitis though suppressing inflammatory response. To test this hypothesis, we induced pancreatitis in mice, producing different degrees of severity by repeated injections of cerulein with or without lipopolysaccharide (LPS). Local injuries of pancreas and lung were assessed by established parameters, and systemic inflammation was determined through assaying the serum TNF-α and IL-6 levels and myeloperoxidase (MPO) activity. The effects of RvD1 on inflammatory response in acute pancreatitis were studied in detail. Our findings provide a novel therapeutic approach for anti-inflammatory treatments in acute pancreatitis.
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MATERIAL AND METHODS
Animals and Reagents
Adult male C57BL/6 mice (20-25 g) were obtained from the Animal Centre of Sichuan University (Chengdu, China), maintained on a 12 h light/12 h dark cycle at 22˚C, given water ad libitum, fed standard laboratory chow, and allowed to acclimatize for a minimum of 1 week. Mice were randomly assigned to control or experimental groups. All experiments were conducted with the approval of the Animal Research Committee at Sichuan University. Cerulein and lipopolysaccharide (LPS) were purchased from Sigma Chemical (Sigma-Aldrich, St. Louis, Missouri, USA). RvD1 was purchased from Cayman Chemical (Cayman, Michigan, USA).
Antibodies against NF-κB p65 subunit and histone H3.1 were purchased from Cell Signaling Technology (CST, Massachusetts, USA). Other items were purchased from standard suppliers or as indicated in text.
Induction of experimental pancreatitis
For cerulein pancreatitis, C57BL/6 mice were treated by 7 hourly intraperitoneal injections (IP) of cerulein (50μg/kg/h). More severe acute pancreatitis model was induced by administration of cerulein in combination of LPS (20) , mice were injected intraperitoneally with cerulein in the same way as those in the cerulein acute pancreatitis model except that LPS was added (10 mg/kg) with the last injection of cerulein. Controls received comparable injections of normal saline (NS).
RvD1 (dose of 300ng/mouse based on preliminary data) was administered to the mice by IP 30 min before the first injection of cerulein. Mice were killed 8 h and 24 h after the first injection of cerulein. For RvD1 therapeutic treatment group, RvD1 (dose of 300ng/mouse ) was administered to the mice by IP 4 h after the last injection of cerulein. Mice were killed 24 h after the first 6 injection of cerulein.
Histological examination
Fresh specimens of murine pancreas and lung were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4).Tissues were embedded in paraffin, and 5 mm sections were processed for hematoxylin-eosin (H&E) staining by standard procedures. Then multiple randomly chosen microscopic fields from at least three mice in each group were examined by two pathologists in blind manner. For pancreatic injury, the scoring was on a scale of 0-3 (0 being normal and 3 being severe) according to four items: presence of vacuolization, interstitial edema, interstitial inflammation, the number of acinar cell necroses, as previously described (17) . For lung injury, the scoring was on a scale of 0-4 (0= minimal damage, 1= mild damage, 2= moderate damage, 3= severe damage, 4= maximal damage) according to four items: alveolar congestion, hemorrhage, infiltration or aggregation of neutrophils in air space or the vessel wall, and thickness of the alveolar wall/hyaline membrane formation, as previously described (14) .
Measurement of amylase and lipase
Serum amylase and lipase were determined by means of a commercially available kit (R&D System, MN, USA), and expressed as units per liter (U/L).
Measurement of cytokines
The pro-inflammatory cytokines TNF-α and IL-6 in serum were measured using Luminex assay kit according to the manufacturer's instructions (R&D Systems, MN, USA). Assays were performed in duplicate using the Luminex 100 System (Austin, Texas, USA) Digital images of the bead array were captured following laser excitation and were processed on a computer workstation. Standard curves and reports of unknown samples were prepared using Master QT 7 software (MiraiBio, Alameda, CA, USA).
Measurement of MPO activity
The extent of neutrophil infiltration was measured in both pancreatic and lung tissue by quantifying myeloperoxidase (MPO) activity as previously described (35) . The enzyme activity was determined using MPO detection kit according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The activity was expressed as units per milligram of wet tissue and calculated as % of control as previously described (20) .
Western blot analysis
Pancreatic tissue samples collected at 8h after first injection were homogenized, nuclear protein was extracted separately using the Nuclear Protein Extraction Kit (Viagene Biotech, Ningbo, China) according to the manufacturer's instructions. The concentrations of protein were determined using the BCA method (Pierce, Rockford, USA). Each 20 μg aliquot of protein was loaded in a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, and then transferred onto polyvinylidene difluoride membranes (Millipore, Massachusetts, USA). After complete protein transfer, the membranes were blocked with 5% milk powder solution for 1 h at room temperature, and incubated at 4˚C overnight with rabbit monoclonal anti-NF-κB p65 subunit diluted at a 1:1000 dilution in 5% milk powder solution. For internal reference, a rabbit monoclonal anti-histone H3.1 antibody (1:1000 dilution) was used. After washing the membranes, goat polyclonal anti-rabbit immunoglobulin G secondary antibody (CST, Massachusetts, USA) conjugated to horseradish peroxidase was applied in a 1:5000 dilution and incubated for 1 h at room temperature. Finally, antibody binding was visualized using the enhanced chemiluminescence system (Pierce, Rockford, USA).
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Statistical analysis
Data are expressed as mean ± SEM. All data were analyzed by one-way ANOVA with a posttest analysis (Newman-Keuls). In all cases, a p value of < 0.05 was selected as criterion for statistical significance.
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RESULTS
Effects of RvD1 on the severity of experimental acute pancreatitis
We evaluated the severity of experiment pancreatitis through histological score based on the extent of tissue edema, vacuolization, inflammation, and necrosis. The pancreas histological picture was normal in both control and RvD1 alone treated mice. Cerulein treated mice displayed histological signs of acute pancreatitis characterized by interstitial edema, vacuolization, and infiltration of neutrophil and mononuclear cells with little parenchyma necrosis and hemorrhage.
The treatment of cerulein in combination with LPS caused more severe pathological changes in the pancreatic tissue, with an obvious edema, inflammation, vacuolization, and many local acinar cells necrosis (Fig.1) . In contrast, treatment with RvD1 significantly reduced the morphological changes seen in both models of acute pancreatitis, and decreased the severity of experiment acute pancreatitis (Fig.2D) . Some parameters used to quantify the severity of acute pancreatitis were also measured, such as amylase and lipase. Low levels of serum amylase and lipase activity were evidenced in control and RvD1alone treated mice. Injection of cerulein with or without LPS enhanced serum amylase and lipase activity compared with control mice. Treatment with RvD1 showed a marked reduction in the activity of these pancreatitis markers ( Fig. 2A and B) .
Effects of RvD1 on inflammatory cytokines in experimental acute pancreatitis
To assess pancreatic inflammatory response, we investigate the pro-inflammatory cytokines TNF-α and IL-6, two of the main mediators of the acute-phase response whose levels are useful for predicting the severity of acute pancreatitis (19, 22) . Low TNF-α and IL-6 levels were evidenced in the serum of control and RvD1 alone treated mice. The TNF-α and IL-6 serum levels revealed a moderate increase only at early stage after cerulein treatment compared with control animals, while the serum obtained from cerulein plus LPS injected mice showed a marked increase in both cytokines levels. In contrast, treatment with RvD1 significantly reduced the cerulein or cerulein plus LPS induced increase of TNF-α and IL-6 levels, especially in cerulein plus LPS injected mice (Fig. 3) .
Effects of RvD1 on pancreatic MPO activity in experimental acute pancreatitis
MPO was assessed as a quantitative marker of neutrophil infiltration in pancreatic inflammatory disease. Low levels of MPO were detected in the pancreas of control and RvD1alone treated mice.
In contrast, the pancreas obtained from cerulein with or without LPS injected mice showed a marked increase in MPO activity. Treatment with RvD1 inhibited cerulein with or without LPS induced increase in MPO pancreatic levels, and the inhibition role of RvD1 on MPO activity seems more effective in cerulein plus LPS induced mice (Fig. 2C) .
Effects of RvD1 on pancreatic NF-κB activation in experimental acute pancreatitis
Pancreatic tissue samples were collected at 8 h after first cerulein administration, and the levels of NF-κB p65 subunit in the nucleus were measured by western blot (Fig. 4A ). Cerulein and cerulein plus LPS both induced increased levels of NF-κB p65 subunit in the nucleus, with a more pronounced increase of NF-κB p65 subunit in cerulein plus LPS induced mice. In contrast, treatment with RvD1 inhibited cerulein with or without LPS induced NF-κB p65 subunit increase in the nucleus (Fig. 4B) .
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Effects of RvD1 on severity of acute pancreatitis associated lung injury
We also evaluated the severity of acute pancreatitis associated lung injury based on histological alternation including alveolar congestion, hemorrhage, neutrophils infiltration in air space and thickness of the alveolar wall. The lung histological picture was normal in control and RvD1alone treated mice. In mice treated by cerulein with or without LPS, lung damage was characterized by alveolar congestion, obvious hemorrhage, infiltration of neutrophil in air space and increased thickness of the alveolar wall (Fig. 5) . Treatment with RvD1 significantly reduced the histological alterations of lung injury (Fig. 6B) . MPO was also assessed as a quantitative marker of neutrophil infiltration in lung inflammatory response. Low levels of MPO were detected in the lung tissues of control and RvD1alone treated mice. In contrast, the lung tissues obtained from cerulein with or without LPS injected mice showed an increase in MPO activity, with a more pronounced increase of MPO activity in cerulein plus LPS induced mice. In lung tissues of additional RvD1 treated mice, there was significantly less MPO activity as compared with cerulein or cerulein plus LPS induced mice, respectively (Fig. 6A) . Overall, these finding indicated that pretreatment of RvD1 reduced the severity of acute pancreatitis associated lung injury.
Therapeutic treatment of RvD1 reduced the severity of experimental acute pancreatitis
We further evaluated the severity of experimental pancreatitis with RvD1 therapeutic treatment.
Application of RvD1 4h after induction of acute pancreatitis, either by cerulein or cerulein plus LPS, could significantly alleviate pancreatic inflammation, which was evaluated by pancreatic morphological changes (Fig. 7) , pancreatic injury scoring, pancreatic MPO activity and serum amylase and lipase activity (Fig. 8) .
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DISCUSSION
Acute pancreatitis is a potentially fatal disease characterized by wide clinical variation, ranging from a mild self limiting to severe disease complicated by sepsis and multi-organ failure, leading to high morbidity and mortality rates (8, 41) . Currently, despite the development of new diagnostic tools and treatment options, there are several problems in the therapy of severe acute pancreatitis (26, 44) . In this study, we induced acute pancreatitis in two different mouse models characterized by different degrees of severity. In mice, acute pancreatitis induced by cerulein alone represents relatively mild type, focal necrosis possibly could be detected but customarily little parenchyma necrosis occurs. Acute pancreatitis is a kind of special inflammatory disease that in could arouse systemic inflammatory responses (SIRS), which cause 'injury in distant organ more severe than that in pancreas', this is typically observed clinically. In pancreatitis induced SIRS, lung is the most susceptible organ and significant changes are primarily detect in lungs. Our results demonstrate that cerulein alone induced a relatively mild model of acute pancreatitis with moderate increased leukocyte infiltration in lung tissues. In contrast, combination of cerulein and LPS injection induced more severe model with deteriorated pancreatic inflammation, evident local acinar necrosis, as well as drastic systemic inflammatory responses, accompanied by more severe lung injury. Despite the difference in the two models of acute pancreatitis, we discovered the significant therapeutic role of RvD1 in both models no matter the presence or absence of LPS, though it is a little more protective in the severe form of the disease. Thus, RvD1could be a representative agent of a novel class of drugs to be proposed for an innovative treatment of severe acute pancreatitis.
As the results showed, RvD1 administration in mice subjected to cerulein and LPS induced 13 severe acute pancreatitis caused a marked reduction in the level/activity of the markers of pancreatitis severity. In this study, RvD1 treatment decreased serum lipase and amylase activity in experiment pancreatitis. The results of the present study also show that cerulein and LPS caused a significant enhancement in the serum levels of TNF-α and IL-6. These inflammatory cytokines are two of the principal mediators of the acute-phase response, and they have been suggested as markers for predicting the severity of acute pancreatitis (19, 22) . In view of the well established anti-inflammatory properties of RvD1 (2, 34), in this study, the administration of RvD1 significantly inhibited the production of TNF-α and IL-6. There are also evidences demonstrated that blockades of these inflammatory cytokines attenuate the disease process in experimental pancreatitis (3, 25) . Furthermore, TNF-α and IL-6 are basic regulators of all neutrophil functions and MPO is a well known marker of neutrophil infiltration in inflammatory disease (10, 37) . In the present study, cerulein and LPS stimulation caused enhanced MPO levels in both pancreatic and lung tissue, while RvD1 treated mice showed a significant decrease of the enzymatic activity, thus suggesting a reduced recruitment of neutrophils inside the pancreatic and lung tissue. Both biochemical and molecular data very well correlated with the histological results. Indeed, in pancreas samples obtained from cerulein and LPS injected mice, we observed a marked edema, an increased neutrophil infiltration, local necrosis and a high degree of vacuolization those were abated by treatment with RvD1. Moreover, cerulein and LPS induced lung injury characterized by alveolar congestion, obvious hemorrhage, infiltration of neutrophil in air space and increased thickness of the alveolar wall those were also attenuated by treatment with RvD1.The effects of RvD1 were confirmed in cerulein alone induced mild acute pancreatitis. Therefore, our findings indicate that pretreatment of RvD1 produces beneficial effects on the disease process.
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The signaling pathway responsible for the role of RvD1 in regulating inflammatory response during the course of acute pancreatitis has been of interest. One important signaling molecule, NF-κB, was identified as an important regulator of the expression of many inflammatory mediators in the pancreas (5) . There is an emerging body of evidence which suggests that NF-κB plays an important role in the early stage of acute pancreatitis, and that inhibiting this transcription factor reduces the disease severity (7, 29, 31) . Most researchers agree that blocking NF-κB activation is beneficial in acute experimental pancreatitis (13, 28) . Here, we show that NF-κB activation gradually increased after induction of pancreatitis, especially in cerulein and LPS In line with these observations, our data showed that RvD1 significantly inhibited both the cerulein and cerulein in combination with LPS induced NF-κB activation in experiment pancreatitis in mice, as a result, pro-inflammatory cytokines, amylase and lipase in plasma, as well as neutrophil infiltration in both pancreas and lung were reduced, ameliorating the acute pancreatitis and associated lung injury.
Furthermore, Wang et al. also showed that RvD1 has a therapeutic effect 8 hours after LPS administration (43) . Indeed, our further data confirmed that therapeutic treatment of RvD1 4 h after induction of acute pancreatitis also significantly reduced the severity of experimental acute pancreatitis. Mice treated with therapeutic RvD1 showed significant decrease of digestive enzyme activity and pancreatic MPO activity, as well as the histological results. In pancreas samples obtained from cerulein and LPS injected mice, we observed a marked edema, an increased neutrophil infiltration, local necrosis and a high degree of vacuolization those were abated by therapeutic treatment with RvD1 4 h after induction of acute pancreatitis. This data suggested that RvD1 has a therapeutic effect in cerulein induced experimental acute pancreatits even through the pancreatic inflmmation has been originated.
In conclusion, our data demonstrates that RvD1 is capable of improving injury of pancreas and lung, and exerting anti-inflammatory effects may through the inhibition of NF-κB activation in experimental acute pancreatitis in mice, with even more notable protective effect in severe acute pancreatitis. Therefore, our present findings provide the potential for the development of an innovative therapeutic approach for the management of severe pancreatitis in humans. 
